Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07092566 · ClinicalTrials.gov registry record · Phase 3
R.E.C.K vs Exparel in Robotic Nephrectomy
A Phase 3 study of Pain Management and Renal Carcinoma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT07092566 is a Phase 3 study of Pain Management and Renal Carcinoma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 170 participants, above the 149-participant average among 31 other Pain Management trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07092566, a Phase 3 study of Pain Management and Renal Carcinoma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
Conditions Studied
Interventions
- DRUG Ketorolac
- DRUG Epinephrine
- DRUG Exparel
- DRUG Ropivacaine HCL
- DRUG Clonidine HCL
Study Locations (1)
North Carolina
- Levine Cancer - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2025-11-14 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07092566
The ClinicalTrials.gov registry entry for NCT07092566 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 149-participant average among 31 other Pain Management trials with a reported enrollment target (14% higher). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pain Management appearing as the primary indexed condition, and to 5 interventions - of which Ketorolac is the first listed.
NCT07092566 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07092566 about?
NCT07092566 is a clinical study titled "R.E.C.K vs Exparel in Robotic Nephrectomy". The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain sco...
What is the current status of trial NCT07092566?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2025-11-14. Estimated completion is 2027-10.
What conditions does trial NCT07092566 study?
This clinical trial studies the following conditions: Pain Management, Renal Carcinoma, Nephrectomy / Methods.
What interventions are being tested in trial NCT07092566?
The interventions under investigation include: Ketorolac (DRUG), Epinephrine (DRUG), Exparel (DRUG), Ropivacaine HCL (DRUG), Clonidine HCL (DRUG).
Who is sponsoring clinical trial NCT07092566?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07092566 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty
ACTIVE NOT RECRUITING · Phase 3
-
Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection
ACTIVE NOT RECRUITING · Phase 3
-
Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy
COMPLETED · Phase 3
-
Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
COMPLETED · Phase 3
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.